Investigation of Hypophosphataemia Following Intravenous Iron

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Total Enrollment

40 participants

Study Classification

OBSERVATIONAL

Study Start Date

2019-10-07

Study Completion Date

2020-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Anaemia (low haemoglobin levels) can develop in a number of conditions, including chronic kidney disease (CKD) and intestinal conditions (e.g. inflammatory bowel disease, intestinal failure). Intravenous iron can be given to patients with these conditions to help correct their aneaemia. However, intravenous iron has been associated with the development of low phosphate levels - hypophophosphataemia. The aim of this study is to determine potential causes of hypophosphataemia following administration of intravenous iron.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Short-Term Effects & Safety of an Accelerated Intravenous Iron Regimen in Patients With Heart Failure

NCT01925703

Heart Failure Iron Deficiency Anemia

COMPLETED PHASE4

Iron Deficiency Anemia in Childern With Liver Cirrhosis

NCT03482076

Iron Deficiency, Anaemia in Children Liver Cirrhosis

UNKNOWN NA

Intravenous Iron in Patients With Severe Chronic Heart Failure and Chronic Kidney Disease

NCT00384657

Chronic Kidney Disease Chronic Heart Failure Anemia

WITHDRAWN PHASE3

Hospitalization & Mortality in Patients With Iron Deficiency CKD and HF Treated With i.v. Iron.

NCT02392910

Iron Deficiency Heart Failure Chronic Kidney Disease

COMPLETED PHASE4

Hypophosphatemia With Ferric Carboxymaltose Vs. Iron Dextran in Iron Deficiency Secondary to Heavy Uterine Bleeding

NCT01307007

Iron Deficiency Anemia

COMPLETED PHASE2

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Low levels of iron can lead to anaemia, known as iron deficiency anaemia, which can be debilitating due to symptoms such as shortness of breath, fatigue, and dizziness. Iron deficiency anaemia can be treated by giving iron supplementation. Iron supplements can be taken orally or can be given intravenously (through the veins). Giving iron intravenously has advantages over iron supplements taken orally, which can cause side effects such as stomach pain and cramping. However, giving iron intravenously has been associated with the development of low levels of phosphate in the blood. This is known as hypophosphataemia. Phosphate is an important salt in the body and has a number of important functions. Very low levels of phosphate can cause muscle pain, disorientation, seizures and heart problems. It is unclear why giving iron intravenously can cause hypophosphataemia. This project aims to investigate the potential causes of hypophosphataemia in patients who receive intravenous iron as treatment for anaemia associated with their condition. Patients with chronic kidney disease (CKD) and intestinal failure will be recruited to the study, since people with CKD may handle iron differently than those with healthy kidneys. Samples will be taken at two time points: prior to giving the intravenous iron and at the patient's next appointment. Healthy volunteers will also be recruited to the study to allow comparison between the groups receiving iron and those who do not receive iron. Samples will be analysed to determine potential causes of hypophosphataemia. Results from before and after iron is given will be compared to determine if any of the participants developed hypophosphataemia and if any other test are affected which may explain why this has developed.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Hypophosphatemia Chronic Kidney Diseases Intestinal Disease Anemia

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

CASE_CONTROL

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Chronic Kidney Disease

This group will consist of 10 patients who have previously been diagnosed with chronic kidney disease and are receiving intravenous iron due to anaemia.

No interventions assigned to this group

Intestinal failure

This group will consist of 10 patients who have previously been diagnosed with intestinal conditions and are receiving intravenous iron due to anaemia.

No interventions assigned to this group

Healthy Volunteers

This group will consist of 20 healthy volunteers. This group will act as a comparator for the CKD and intestinal failure groups.

No interventions assigned to this group

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

For Patients

* aged 18 years or older
* previously diagnosed with intestinal failure or advanced CKD
* have anaemia requiring administration of intravenous iron
* be able to adequately speak and understand English
* Have capacity to give written informed consent

For Healthy Volunteers

* aged 18 years or more
* be able to adequately speak and understand English
* have capacity to give written informed consent

Exclusion Criteria

For patients

* have dialysis-dependent CKD
* participation in any other study which will affect results of the current study

For Healthy Volunteers

* have CKD (eGFR \<60 mls/min/1.73\^2)
* history of any form of metabolic bone disease
* Participation in any other study which will affect the results of the current study

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes